延缓糖尿病进展试验(TRIPOD):使用无线技术和激励措施的随机对照试验研究方案
TRIPOD是一项在新加坡开展的随机、开放标签、对照、多中心、优效性试验,纳入339例血糖控制欠佳的2型糖尿病成人(自我报告HbA1c 7.5-11.0%),按1:1:1随机分为常规护理组、常规护理+综合糖尿病管理包(DMP)组、常规护理+DMP+财务激励计划M-POWER Rewards组,主要结局为第12个月HbA1c较基线的平均变化,并评估成本效果。
要点
- TRIPOD为三臂平行随机对照优效性试验,纳入339例自我报告HbA1c 7.5-11.0%的2型糖尿病成人。
- 主要结局为第12个月HbA1c较基线的平均变化,次要结局包括第6、18、24个月HbA1c变化及多项自我管理指标。
- 将计算第12个月HbA1c改善的增量成本效果比,并转换为每获得一个质量调整生命年的成本。
核心结论
- TRIPOD研究将提供关于干预措施长期成本效果和财务可行性以及整合入常规护理潜力的见解。
研究设计与样本
- TRIPOD为随机、开放标签、对照、多中心、优效性试验,设三个平行组:仅常规护理、常规护理加综合糖尿病管理包(DMP)、常规护理加DMP加财务激励计划M-POWER Rewards。
- 共339例血糖控制欠佳的2型糖尿病成人(自我报告HbA1c 7.5-11.0%)将按1:1:1区组随机分配至三组。
- 主要结局为第12个月HbA1c较基线的平均变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcomes for those with type 2 diabetes mellitus (T2DM) in Singapore are poor. In this TRIal to slow the Progression Of Diabetes (TRIPOD), we will evaluate the effectiveness and cost-effectiveness of a comprehensive diabetes management package (DMP), with or without a financial incentives program, M-POWER Rewards, in efforts to improve HbA1c levels for individuals with T2DM. METHODS/DESIGN: TRIPOD is a randomized, open-label, controlled, multi-center, superiority trial with three parallel arms: (1) usual care only, (2) usual care with DMP, and (3) usual care with DMP plus M-POWER Rewards. A total of 339 adults with sub-optimally controlled T2DM (self-reported HbA1c 7.5-11.0%) will be block randomized according to a 1:1:1 allocation ratio to the three arms. The primary outcome is mean change in HbA1c level at Month 12 from baseline. Secondary outcomes include mean change in HbA1c level at Months 6, 18, and 24; mean changes at Months 6, 12, 18, and 24 in weight, blood pressure, and self-reported physical activity, weight monitoring, blood glucose monitoring, medication adherence, diabetes self-management, sleep quality, work productivity and daily activity impairment, and health utility index; and proportion of participants initiating insulin treatment by Months 6, 12, 18, and 24. Incremental cost-effectiveness ratios will be computed based on costs per improvement in HbA1c at Month 12 and converted to cost per quality-adjusted life year gained. DISCUSSION: The TRIPOD study will present insights about the long-term cost-effectiveness and financial viability of the interventions and the potential for integrating within usual care. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03800680. Registered on 11 January 2019.
引用
- Lim RSM, Gardner DSL, Bee YM, et al. TRIal to slow the Progression Of Diabetes (TRIPOD): study protocol for a randomized controlled trial using wireless technology and incentives. Trials. 2019. PMID: 31779678. doi:10.1186/s13063-019-3749-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。